Skip to content
Search

Latest Stories

Air India to send pilots on deputation to Vistara

Full-service airline Vistara, a Tata joint venture with Singapore Airlines, has reduced 25-30 flights daily due to pilot shortage

Air India to send pilots on deputation to Vistara

Tata Group-owned Air India is planning to send a set of first officers to Vistara, which is grappling with a pilot shortage, according to multiple sources.

The pilots will be sent to Vistara, a Tata joint venture with Singapore Airlines, on deputation, subject to getting necessary regulatory approvals. Air India and Vistara did not offer any comments.


The sources told PTI that some first officers who can operate A320 family planes will be sent to Vistara on deputation.

Two sources said the number of pilots likely to be deputed to Vistara could be over 30.

One of the sources said it will be the first time that pilots from Air India will be deputed to Vistara for operating narrow-body aircraft.

For operating Vistara's wide-body Boeing 787 planes, around 24 pilots are already on deputation from Air India.

Vistara has cut its operational capacity by 10 per cent or 25-30 flights daily due to pilot issues.

The full-service carrier has around 6,500 staff, including 1,000 pilots and 2,500 cabin crew. The airline is in the process of merging with Air India.

Recently, the airline faced significant flight disruptions due to non-availability of crew.

Many pilots had reported sick to protest against the new contract that would result in pay revisions and there were also roster issues.

Vistara has a fleet of 70 aircraft, including 53 Airbus A320 neos, 10 Airbus A321s, and 7 Boeing 787-9 Dreamliner aircraft.

On April 5, Vistara CEO Vinod Kannan told PTI that flight disruptions were mainly caused by a stretched roster for pilots and the operations would normalise by May. (PTI)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less